GILEAD SCIENCES INC

Gilead’s new Ebola trial in the DRC shows how remdesivir could capture a $12 bn outbreak‑phase market, boosting revenue, ROI and brand trust while offering cost‑effective, rapid‑response therapy.

Gilead’s platform‑driven strategy expands beyond oncology, delivering promising cell‑based therapies for autoimmune, cardiovascular, and infectious diseases with solid safety and regulatory progress.

Explore how Gilead Sciences’ focus on antivirals drives stock performance, clinical success, and regulatory wins—insights that shape investor outlook.

Gilead Sciences’ steady Q4 results show modest revenue growth, a robust hepatitis‑B launch, and a diversified Phase III pipeline that may drive future gains.

Gilead’s FDA acceptance of Yeztugo’s sNDA marks a key milestone for its once‑weekly HIV PrEP, while insider share sales confirm routine liquidity activity and highlight investor confidence.

Gilead Sciences Q1 2026 earnings hit $1.34 EPS, yet analyst targets swing from $90 to $135 as new hepatitis‑B and immuno‑oncology candidates promise upside, while patent expirations loom.

Gilead Sciences advances obeldesivir for Ebola and tro delvy for triple‑negative breast cancer, showing promise in regulatory approvals and clinical trials.

Gilead Sciences shares executive equity awards, updated financials and a roadmap for next‑gen antivirals, patent strategy, and M&A moves to stay ahead of pricing pressures and rivals.

Gilead’s Q4 2025 earnings reveal steady antiviral revenue and rapid growth in oncology assets like Gidea, impacting investors and patient access in biopharma.

Gilead’s share dip reveals how short‑term volatility intertwines with long‑term CAR‑T strategy, amid rising oral myeloma agents and heavy peer investments.